NCT02153580View on ClinicalTrials.gov

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 24, 2014

Primary Completion Date

September 2, 2026

Study Completion Date

September 2, 2026

Conditions
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaB-Cell Prolymphocytic LeukemiaHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedPost-Transplant Lymphoproliferative DisorderRecurrent Adult Burkitt LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Hairy Cell LeukemiaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic Lymphoma
Interventions
BIOLOGICAL

Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Given IV

DRUG

Bendamustine Hydrochloride

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Etoposide

Given IV

DRUG

Fludarabine Phosphate

Given IV

Trial Locations (1)

91010

City of Hope Comprehensive Cancer Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER